Cannabinoid Pharmacokinetics
Cannabinoid Pharmacokinetics - Related Videos
02:31
Detection of Orexin and Cannabinoid Receptor Co-localization in Diet-Induced Obese Zebrafish
0 Views •
2025
This video demonstrates a protocol for investigating the co-localization of orexin and cannabinoid receptors in normal and diet-induced obesity (DIO) adult zebrafish brain tissue using immunofluorescence.
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
0 Views •
Cited by 59 •
2016
Rabbits are widely used to study the pharmacokinetics of intraocular drugs. We describe a method for conducting pharmacokinetic studies of intraocular drugs using rabbit eyes.
01:24
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
0 Views •
2024
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:21
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
0 Views •
2024
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy. Two synthetic agonists of THC,...
01:10
Pharmacokinetics: Overview
0 Views •
2023
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
FAQs
Cannabinoids’ high lipophilicity promotes distribution beyond the bloodstream and contributes to tissue storage. Plasma protein binding also influences how much compound remains available for distribution or pharmacological action. Together, these properties help determine how concentrations change over time and why effects may persist beyond the initial rise in circulating cannabinoid levels.
The administration route shapes the resulting concentration profile. Oral and inhaled delivery can differ in the timing, intensity, and duration of cannabinoid exposure, so the same compound may produce different pharmacological patterns depending on how it enters the body. Comparing routes is therefore important when interpreting effects or planning cannabinoid-based treatment.
Hepatic cytochrome P450 enzymes contribute to cannabinoid metabolism and can alter the amount of cannabinoid present in the body. Interactions involving these enzymes may change cannabinoid exposure or modify concentrations of other medicines. This mechanism makes metabolic interaction assessment important when cannabinoids are considered alongside conventional drug therapy.
Concentration profiles show how cannabinoid levels change after administration and help relate exposure to the timing, intensity, and duration of pharmacological effects. Researchers can compare profiles produced by different delivery routes and use the results to evaluate whether a dosing approach provides a suitable exposure pattern for a particular therapeutic investigation.
Pharmacokinetic analysis supports individualized dosing by examining factors that control cannabinoid exposure, including administration route, plasma protein binding, tissue storage, and hepatic metabolism. Understanding these influences helps clinicians and researchers account for differences in concentration profiles rather than relying only on a uniform dose when developing or evaluating cannabinoid-based treatments.
Therapeutic monitoring uses pharmacokinetic information to evaluate cannabinoid exposure during treatment and to support safer dose decisions. Monitoring is especially relevant when cytochrome P450-mediated interactions could alter cannabinoid or other medicine concentrations. In medical research, these assessments also help evaluate drug interactions and guide the safer development of cannabinoid therapies.